Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

o be steady.  Our total revenues for the fourth quarter of 2010 were $101.6 million, the first time we have exceeded $100 million for the quarter."

Net Product Revenue (in millions)Three Months Ended December 31,Years Ended December 31, 20102009$ Change% Change20102009$ Change% ChangeNaglazyme (1) $

45.1$

44.4$

0.71.6%$

192.7$

168.7$

24.014.2%Kuvan (2) 27.322.74.620.3%99.476.822.629.4%Firdapse (3) 3.00.03.0N/A6.40.06.4N/A(1) Changes in foreign currency rates, net of hedges, had a negative $0.1 million impact on Naglazyme sales in the three months ended December 31, 2010 and a negative $1.7 million impact on Naglazyme sales for the year ended December 31, 2010.  Naglazyme revenues experience quarterly fluctuations due to the timing of government ordering patterns in certain countries.

(2) The quantity of commercial tablets dispensed to patients in the U.S. increased 5.0 percent in the fourth quarter of 2010 compared to the third quarter of 2010 and increased 16.4 percent in the fourth quarter of 2010 compared to the fourth quarter of 2009.

(3) A product for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS) which was launched in the EU in April 2010. Three Months Ended December 31, Years Ended December 31,20102009$ Change% Change 20102009$ Change% Change Aldurazyme revenue reported by Genzyme (4) $

42.5 $

38.7 $

 3.8 9.8%$

166.8 $

155.1 $

11.7 7.5%Royalties due from Genzyme 17.8 15.7  2.1   68.0   61.8   6.2 Incremental (previously recognized) Aldurazyme
product
transfer
revenue   5.3   1.1  4.2 3.2 8.4  (5.2)Total Aldurazyme net product revenues (5)$

23.1 $

16.8 $

 6.3 $

  71.2 $

  70.2 $

  1.0 (4) Changes in foreign currency rates caused a decrease to Aldurazym
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... DIEGO, Aug. 12, 2011 / PRNewswire/ -- Halozyme ... company developing and commercializing products targeting the extracellular ... at the Wedbush 2011 Life Sciences Conference in New ... at 9:10 a.m. EDT (6:10 a.m. PDT). To listen ...
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
(Date:7/9/2014)... microbiologists from the Keck School of Medicine of ... that mice lacking a specific component of the ... potentially fatal complication of infection. The discovery suggests ... reduce inflammation in human autoimmune and hyper-inflammatory diseases ... , The study was published online on June ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory have ... design of a "medical synchrotron" capable of delivering precision ... damage to surrounding healthy tissue. The new device would ... systems, potentially increasing the availability and benefits of this ...
... There is a new,Internet service available that changes the ... stay informed, it allows,long-term care providers to give them regular ... text message without families having,to call, no matter where they ... to do and too little time. It,s a common problem ...
... and digital radiography highlighted at RSNA 2008 , ... Siemens Healthcare ( ... from fluoroscopy and digital radiography to interventional radiology, at ... Radiological Society of North America (RSNA) from November 30 ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today that ... Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at ... , The live and archived ... of Events" in the Idenix Investor Center at www.idenix.com ...
... Inc.,(Nasdaq: CEPH ) and ImmuPharma PLC (LSE: ... have signed an Option Agreement,providing Cephalon with an option ... Lupuzor(TM) for the treatment of Systemic Lupus,Erythematosus. ImmuPharma ... in patients in Europe and Latin America. , ...
... 25 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... monoclonal antibodies for the treatment of serious ... U.S. Patent and Trademark,Office has issued U.S. ... covering anti-viral applications of antibodies that directly ...
Cached Medicine News:Health News:Physicists receive patent for improved cancer therapy device 2Health News:Physicists receive patent for improved cancer therapy device 3Health News:New Internet Service Delivers Relief to Families of Those in Long-Term Care 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 3Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 4Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 5Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 6Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 2Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 3Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 4Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: